# Multiple Ascending Doses of AMG 139 in Healthy and Crohn's Disease Subjects

> **NCT01258205** · PHASE1 · COMPLETED · sponsor: **AstraZeneca** · enrollment: 48 (actual)

## Conditions studied

- Crohn's Disease

## Interventions

- **DRUG:** AMG 139

## Key facts

- **NCT ID:** NCT01258205
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-02-28
- **Primary completion:** 2015-02-18
- **Final completion:** 2015-02-18
- **Target enrollment:** 48 (ACTUAL)
- **Last updated:** 2021-05-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01258205

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01258205, "Multiple Ascending Doses of AMG 139 in Healthy and Crohn's Disease Subjects". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01258205. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*